TMDI - Titan Medical Inc.
| Previous Close | 0.5020 |
| Open | 0.5395 |
| Bid | 0.4922 x 900 |
| Ask | 0.5149 x 1100 |
| Day's Range | 0.5050 - 0.5398 |
| 52 Week Range | 0.3800 - 4.6500 |
| Volume | 340,047 |
| Avg. Volume | 568,616 |
| Market Cap | 18.353M |
| Beta (5Y Monthly) | 6.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Titan Medical and Cambridge Design Partnership Announce Expanded Engagement for Robotic Instrument Development
Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery ("MIS"), and Cambridge Design Partnership Ltd. ("CDP"), a leading patient-centric product and technology innovation company specializing in the healthcare sector, today announce an expanded engagement in respect of the instrument development program for Titan’s single-port robotic surgical system. Additionally, CDP has subscribed for common shares of Titan.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Titan Medical Inc. (NASDAQ:TMDI)
Is Titan Medical Inc. (NASDAQ:TMDI) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]
- Business Wire
Titan Medical Announces New Common Share Purchase Agreement With Aspire Capital Fund of up to US$35 Million
Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery ("MIS"), announces that it has entered into a Common Share Purchase Agreement (the "Agreement") with Aspire Capital Fund, LLC ("Aspire Capital") where Aspire Capital has committed to purchase up to US$35.0 million of common shares of Titan at Titan’s request from time to time, until June 23, 2022. This new Agreement replaces the prior Common Share Purchase Agreement announced on August 29, 2019, which has been terminated upon entering into this Agreement.
- Benzinga
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- Business Wire
Titan Medical Confirms Receipt of Deficiency Notices From Nasdaq
Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery ("MIS"), today announced that on November 27, 2019, the Company received notification from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares (the "Shares") listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US$1.00 for a period of 30 consecutive business days.
- Business Wire
Titan Medical to Participate in Two Investment Conferences in December
Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that Company management will be participating in two upcoming investor conferences. The Benchmark Company’s 8th Annual Discovery One on One Investor Conference being held at the New York Athletic Club in New York City on Wednesday, December 4, 2019. The 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in New York City.
- Business Wire
Titan Medical Reports Third Quarter 2019 Financial Results
Titan Medical Inc. , a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery , announces financial results for the three and nine months ended September 30, 2019.
- Business Wire
Titan Medical Determines Not to Proceed with Public Offering
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has determined not to proceed with the public offering of units of the Company for which it filed a final short form prospectus on October 31, 2019. The Company has made this decision based on its assessment of market conditions, and intends to pursue alternative financing options. Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS.
- Business Wire
Titan Medical Announces Filing of Final Prospectus
Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has filed and been receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at a price of US $0.45 per Unit for minimum gross proceeds of US $15,000,000 and maximum gross proceeds of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).
- Business Wire
Titan Medical Announces Pricing of Marketed Offering
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $0.45 per Unit for total gross proceeds of a minimum of US $15,000,000 and a maximum of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- Business Wire
Titan Medical Announces Filing of Amended and Restated Preliminary Prospectus and Withdrawal of Previously Published Milestones
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has filed and been receipted for an amended and restated preliminary short form prospectus (the “A&R Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan has also filed a corresponding registration statement on Form F-10 (the “Registration Statement”) with the United States Securities and Exchange Commission under the U.S.-Canada Multijurisdictional Disclosure System. Each of these filings is in connection with a proposed marketed offering of units (the “Units”) of the Company (the “Offering”) for total gross proceeds of a minimum of US$15,000,000 and a maximum of US$25,000,000.
- Business Wire
Titan Medical Continues to Market Offering of Units
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced on Monday, September 23, 2019 that it had filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan had also filed a corresponding registration statement on Form F-10 (the “Registration Statement”) with the United States Securities and Exchange Commission under the U.S.-Canada Multijurisdictional Disclosure System. On September 24, 2019, the Company announced that in consultation with its financial advisors it had switched from an overnight marketed offering to a fully marketed offering (the “Offering”) and that it expected to price the offering no later than September 27, 2019.
- Benzinga
The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...
- Zacks Small Cap Research
TMDI: Titan Medical: Revolutionizing Minimally Invasive Surgery with Robotics!
Titan Medical Inc. (TMD.TO) (TMDI) based in Toronto, Canada designs and develops computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). In the last decade, Titan has been focused on developing a single-port system for abdominal surgery which promises ease of use, design characteristics for superior clinical performance, operating room efficiency and cost benefit to hospitals. Stability and consistency of outcomes are of prime importance in interventional procedures since anatomical structures are complex and can be punctured easily.
